Antibiotics R&D takes another hit as Achaogen slashes research ops in reorganization
There’s more bad news for the antibiotics R&D field Thursday evening.
A few weeks after the FDA green-lighted Achaogen’s $AKAO antibiotic Zemdri (plazomicin) for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
